TG
REGN icon

TCW Group’s Regeneron Pharmaceuticals REGN Stock Holding History

TCW Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
1,695
+30
+2% +$20.4K 0.01% 378
2026
Q1 		$1.29M Sell
1,665
-374
-18% -$286K 0.01% 327
2025
Q4 		$1.57M Buy
+2,039
New +$1.38M 0.01% 304
2015
Q2 		– Sell
-21,450
Closed -$9.68M – 708
2015
Q1 		$9.68M Buy
21,450
+650
+3% +$275K 0.05% 255
2014
Q4 		$8.53M Sell
20,800
-15,350
-42% -$6.04M 0.04% 296
2014
Q3 		$13M Sell
36,150
-3,850
-10% -$1.29M 0.05% 275
2014
Q2 		$11.3M Buy
40,000
+850
+2% +$252K 0.05% 313
2014
Q1 		$11.8M Buy
39,150
+300
+0.8% +$92.4K 0.05% 299
2013
Q4 		$10.7M Buy
38,850
+350
+0.9% +$101K 0.05% 319
2013
Q3 		$12M Buy
38,500
+1,050
+3% +$276K 0.06% 274
2013
Q2 		$8.42M Buy
+37,450
New +$8.72M 0.04% 339

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

TCW Group's REGN Position: Q2 2026 in Review

TCW Group increased its Regeneron Pharmaceuticals (REGN) stake by 1.8% in Q2 2026, buying an estimated $20.4K and bringing the position to 1,695 shares worth $1.06M. The position accounts for 0.01% of the portfolio, ranked #378.

TCW Group first reported a position in REGN in Q2 2013 and has held it in 11 quarters since. The position peaked at $13M in Q3 2014. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • TCW Group held 1,695 shares of Regeneron Pharmaceuticals worth $1.06M as of Q2 2026.
  • TCW Group bought 30 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $20.4K.
  • Regeneron Pharmaceuticals made up 0.01% of TCW Group's portfolio in Q2 2026, its #378 holding.
  • TCW Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 11 quarters since.
  • TCW Group's Regeneron Pharmaceuticals position peaked at $13M in Q3 2014.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on TCW Group's 13F filing for Q2 2026, filed 3 Aug 2026.